An observational study in Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma and UTUC, sponsored by Henan Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Henan Provincial People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Carcinoma, Transitional Cell with a site in China — 53 open to participants now, 58 under way, 9 of them phase 3. Carcinoma, Transitional Cell · China.
Among the 90 studies in Carcinoma, Transitional Cell with a site in China, this one is the 6th largest by planned enrollment of the 19 observational ones that give a count, is one of 8 that started in 2019, is one of 19 observational ones, reaches primary completion later than 57 of the 57 other live ones, and was the 80th registered.
633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →53 of the 90 studies in Carcinoma, Transitional Cell with a site in China are open now. Recruiting first, the newest first:
Yunnan Cancer Hospital · Sites in China
Ages 18–80
AstraZeneca · Sites in China, United States, Australia and 13 more countries
Ages 18+
Shanghai Henlius Biotech · Sites in China
Ages 18–70
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Huahui Health · Sites in China, Australia
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 44 · Phase 3 14 · Phase 4 1
First in 2015; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 300 across 107 observational studies indexed under Carcinoma, Transitional Cell.
Median enrollment 58 across the 71 interventional studies, 400 across the 19 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 90 have an industry lead sponsor. The 10 most frequent:
Henan Provincial People's Hospital is the lead sponsor of 63 studies on the registry; 33 are open to participants now.
Henan Provincial People's Hospital has 1 study filed under Carcinoma, Transitional Cell — fewer than ten, so there is no comparison to draw.
20 of the studies in Carcinoma, Transitional Cell with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05302284Phase 3RemeGen Co., Ltd.A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | 2026-12-31 |
| NCT06857175Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) | 2027-06 |
| NCT03967977Phase 3BeiGeneStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | 2027-06-30 |
| NCT06592326Phase 3Mabwell (Shanghai) Bioscience Co., Ltd.9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | 2027-09 |
| NCT05321316Peking University Cancer Hospital & InstituteNectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 90 studies in Carcinoma, Transitional Cell with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC). The study enrolls adult patients presenting with gross or microscopic hematuria and imaging evidence of a space-occupying lesion in the renal pelvis, ureter, or bladder, who are scheduled for diagnostic cystoscopy and/or surgical tissue sampling. Histopathological examination serves as the reference standard.
Stage 1 (Completed, 8th October 2019 - 31st December 2023):
A total of 113 participants have been enrolled. Owing to sufficient research funding, all participants in this stage underwent four urine-based tests: cytology, fluorescence in situ hybridization (FISH), DNA methylation, and a 17-gene mutation panel.
Stage 2 (Ongoing, from 1st January 2024):
The testing protocol was refined to focus on urine DNA methylation alone, owing to limited research funding and the lower cost of DNA methylation compared with the 17-gene mutation panel. As of registration (May 2026), approximately 330 participants have been enrolled.
All enrolled participants are categorized into two groups based on histopathology: a UC group (including upper tract urothelial carcinoma [UTUC] and bladder cancer [BC]) and a non-UC control group. The primary outcome is the diagnostic accuracy (area under the receiver operating characteristic curve [AUC] with 95% confidence interval, sensitivity, and specificity) of the four urine-based tests in the Stage 1 cohort. The key secondary outcome is the diagnostic accuracy of urine DNA methylation in the Stage 2 cohort. Other secondary outcomes include paired comparisons of AUCs among the four tests in the Stage 1 cohort. Exploratory analyses will include the diagnostic performance of urine cytology in a subset of Stage 2 participants with UTUC, as well as subgroup analyses by tumor site (UTUC vs. BC).
Because this study is purely observational and non-interventional, prospective registration was not a regulatory or institutional requirement when enrollment began in 2019. This record is being submitted prior to any data analysis to ensure consistency with current research transparency standards.
Adult patients (≥18 years) presenting with gross or microscopic hematuria, who present with space-occupying lesions in the renal pelvis, ureter, or bladder by imaging (B-ultrasonography, CT, or MRI) and are scheduled for a diagnostic procedure to obtain tissue histopathological diagnosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are eligible if they meet all of the following criteria:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with space-occupying lesions diagnosed with UC by histopathology.
Non-Urothelial Carcinoma Group. Description: Patients with space-occupying lesions not diagnosed with UC.
Diagnostic accuracy of four urine-based tests in the Stage 1 cohort
Area under the receiver operating characteristic curve (AUC) with 95% confidence interval (CI), sensitivity, and specificity of cytology, fluorescence in situ hybridization (FISH), DNA methylation, and a 17-gene mutation panel for the detection of urothelial carcinoma (UC) in the Stage 1 cohort, using histopathology as the reference standard.
Time frame: At the time of urine collection and subsequent histopathological diagnosis (within 4 weeks of urine collection)
Diagnostic accuracy of urine DNA methylation in the Stage 2 cohort
AUC with 95% CI, sensitivity, and specificity of urine DNA methylation for the detection of UC in all participants enrolled in Stage 2, using histopathology as the reference standard.
Time frame: At the time of urine collection and subsequent histopathological diagnosis (within 4 weeks of urine collection).
Paired comparisons of AUCs among the four tests in the Stage 1 cohort
Paired comparisons of areas under the ROC curves (AUCs) among cytology, FISH, DNA methylation, and the 17-gene mutation panel for detecting UC in the Stage 1 cohort.
Time frame: At the time of urine collection and subsequent histopathological diagnosis (within 4 weeks of urine collection).
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2019 (actual). Primary completion is estimated for Dec 2030, 134 months after the start.
Of 61 observational studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 89. This study's planned 134 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Transitional Cell →
Henan Provincial People's Hospital